Premium
TIME TO HEMATOLOGIC RECOVERY PREDICTS SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH FLUDARABIN, CYCLOPHOSPHAMIDE AND RITUXIMAB – 11 YEARS OF REAL‐WORLD EXPERIENCE
Author(s) -
Mata A. V,
Mesquita I. P,
Alves D,
Medeiros J,
Polo B,
Lopes C,
Costa M. J,
Martins C,
Esteves G,
Lacerda J. F,
Raposo J
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.17_2881
Subject(s) - medicine , rituximab , cyclophosphamide , ighv@ , gastroenterology , chronic lymphocytic leukemia , chemotherapy , progression free survival , progressive disease , minimal residual disease , hematology , fludarabine , surgery , refractory (planetary science) , oncology , leukemia , lymphoma , physics , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom